Jacobs Levy Equity Management Inc. Acquires New Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Jacobs Levy Equity Management Inc. acquired a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 91,909 shares of the company’s stock, valued at approximately $501,000.

Other institutional investors also recently added to or reduced their stakes in the company. Performa Ltd US LLC boosted its position in Maravai LifeSciences by 614.3% during the fourth quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after purchasing an additional 4,300 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Maravai LifeSciences by 3,541.4% during the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock valued at $56,000 after purchasing an additional 9,916 shares in the last quarter. Cibc World Markets Corp bought a new stake in Maravai LifeSciences during the fourth quarter valued at about $56,000. Atria Investments Inc bought a new stake in Maravai LifeSciences during the fourth quarter valued at about $58,000. Finally, Townsquare Capital LLC bought a new stake in Maravai LifeSciences during the fourth quarter valued at about $103,000. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Trading Up 7.1%

Maravai LifeSciences stock opened at $2.10 on Friday. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. Maravai LifeSciences Holdings, Inc. has a 52 week low of $1.67 and a 52 week high of $11.50. The company has a market capitalization of $534.11 million, a price-to-earnings ratio of -1.28 and a beta of 0.19. The stock has a 50-day moving average price of $2.09 and a 200 day moving average price of $4.03.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The firm had revenue of $46.85 million for the quarter, compared to analyst estimates of $44.01 million. The firm’s revenue for the quarter was down 26.9% compared to the same quarter last year. Sell-side analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. UBS Group dropped their price objective on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Robert W. Baird lowered their price target on Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, May 13th. Craig Hallum lowered their price target on Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Stifel Nicolaus set a $5.00 price target on Maravai LifeSciences in a report on Friday, March 21st. Finally, Baird R W downgraded Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Maravai LifeSciences presently has an average rating of “Hold” and a consensus target price of $6.64.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.